Effects of silodosin on sexual function - realistic picture from the everyday clinical practice

The treatment with α1-blockers in patients complaining of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) is associated with potential adverse events (AEs), thus including ejaculatory dysfunction (EjD). We sought to assess the effects of a 3-month course of silodosin 8 mg daily dosing on sexual functioning, mainly including ejaculation and orgasm, in a cohort of 100 consecutive sexually active men in the real-life setting. Patients completed the International Index of Erectile Function-Orgasmic Function (IIEF-OF) domain and the International Prostate Symptom Score (IPSS) both at baseline and at survey. Likewise, patients completed a 16-item self-administered questionnaire with closed questions also including specific questions regarding treatment-related adverse events on sexual functioning. Rates and predictors of OF impairment and drug discontinuation were investigated. At survey, silodosin resulted highly effective in improving IPSS-total and subscales (all p